KNTPF (Kintor Pharmaceutical) Institutional Ownership: 2.93% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KNTPF Kintor Pharmaceutical Ltd KNTPF
26 GF Score
Price $0.25
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical Institutional Ownership?

Kintor Pharmaceutical KNTPF 26 Institutional Ownership is 2.93% as of Jul. 15, 2026. GuruFocus rates KNTPF with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kintor Pharmaceutical's institutional ownership is 2.93%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kintor Pharmaceutical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kintor Pharmaceutical's Float Percentage Of Total Shares Outstanding is 0.00%.

Kintor Pharmaceutical Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical Institutional Ownership Chart

Kintor Pharmaceutical Historical Data

The historical data trend for Kintor Pharmaceutical can be seen below:

2025-08-31 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.09 0.27 0.26 0.21 0.21 0.15 0.07 0.07 0.07 0.07
KNTPF
26GF Score
Kintor Pharmaceutical Ltd KNTPF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 2.93% mean?
Kintor Pharmaceutical (KNTPF) has a Institutional Ownership of 2.93% as of Jul. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kintor Pharmaceutical and its competitors.
Is Kintor Pharmaceutical's Institutional Ownership too high?
Kintor Pharmaceutical's current Institutional Ownership is 2.93%. Overall, Kintor Pharmaceutical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Institutional Ownership compare to VRTX and REGN?
Kintor Pharmaceutical's Institutional Ownership of 2.93% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current Institutional Ownership is 2.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Institutional Ownership of 2.93%. The current Institutional Ownership is 2.93%. Kintor Pharmaceutical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Institutional Ownership is 2.93% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges 09939:Hong Kong
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
26GF Score

Get the complete analysis for KNTPF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price